Verdiva Bio
Develops once-weekly peptide medicines for obesity and cardiometabolic disease, with a lead drug in Phase 2 trials
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-10-28
About Verdiva Bio
Verdiva Bio is a clinical-stage cardiometabolic company developing rationally engineered peptide medicines for obesity, cardiometabolic diseases and related conditions. Its lead program, VRB-101, is an oral formulation of ecnoglutide, a cAMP-biased GLP-1 peptide analog, in Phase 2 development as a once-weekly treatment of obesity.
The pipeline also includes VRB-103, an oral amylin receptor-selective analog that started Phase 1 in July 2026, and injectable candidates VRB-102 and VRB-104, which are in preclinical development. The stated aim is to provide more convenient, patient-friendly treatments for people living with obesity and related conditions.
The company was founded in 2024 and is headquartered in London. It launched in January 2025 with a Series A financing of over $410M. Its CEO is Khurem Farooq, and its board includes representatives of investors such as Forbion, General Atlantic, RA Capital, OrbiMed and Logos Capital.
Product: Investigational peptide drugs for obesity and cardiometabolic disease, including the oral GLP-1 candidate VRB-101 and amylin-based candidates.
Jobs at Verdiva Bio
More biotech & pharma companies
Waymade PLC
Specialty pharmaceutical company developing, licensing and commercialising generic and niche medicines for patients worldwideNew on EvolcWellcome
Charitable foundation funding biomedical research on health challenges and running a free museum and library in LondonNew on EvolcRemote-friendlySalary transparentXap Therapeutics
Cell-based multi-modal therapies for cancer and autoimmune disease, built on a modified immune-cell delivery platformNew on Evolc4C Biomed
Pre-clinical immuno-oncology company finding immune targets and developing antibody drugs for cancer treatmentNew on EvolcAbingdon Analytical
UKAS-accredited stability, shelf-life and method validation testing for diagnostic and medical device developersYoung companyNew on EvolcActimed Therapeutics
Clinical-stage drug developer targeting cancer cachexia and muscle wasting with S-pindolol benzoate in Phase 2New on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Complianz
- Google Analytics 4
- Google reCAPTCHA
- WordPress
- jQuery
- nginx